IL1B and liver mesenchymal hamartoma: From what we have discussed above, a variety of drugs suppressing the NLRP3 inflammasome activation or inhibiting the IL-1β activity may be potential therapies for VMC, while the safety and efficacy of some drugs need further elucidation by more comprehensive animal experiments and clinical trials.